Danaher Corporation announced Monday evening that Julie Sawyer Montgomery has been appointed President and Chief Executive Officer, effective October 1, 2026. The move follows the planned retirement of current CEO Rainer Blair, who will continue to support the company as a senior advisor through March 31, 2027.
The company also stated there is no change to its previously communicated financial outlook for the third quarter and full year 2026. Following the leadership announcement and the reaffirmation of guidance, Danaher shares rose roughly 2% in after-hours trading.
Background on the incoming CEO
Montgomery has been with Danaher since 2017 and most recently served as Executive Vice President with responsibility for the Diagnostics platform. During her tenure leading that platform, the business expanded from roughly $6.0 billion in revenue in 2017 to approximately $11.0 billion at present, while operating profit increased by about threefold, according to the company’s announcement.
Her career at Danaher began at Beckman Coulter Diagnostics, where she held roles in commercial operations and research and development before being named President in 2020. The company noted she brings nearly 25 years of experience spanning healthcare, commercial operations, and R&D.
Board comments and succession context
Steven Rales, Chairman of the Board, characterized the appointment as consistent with the Board’s succession planning. Mitchell Rales, Chairman of the Executive Committee, highlighted that under Montgomery’s leadership the Diagnostics platform has consistently gained share in attractive end markets.
Rainer Blair has led Danaher as President and CEO for the past six years. In that period he participated in the company’s portfolio transformation and guided the firm through the challenges of the COVID-19 pandemic, the company said.
Compensation and incentives
Concurrent with Montgomery’s appointment, Danaher disclosed that it will grant special equity incentive awards to certain key leadership members and founders.
Implications for markets and sectors
The leadership change and the emphasis on the Diagnostics platform are directly relevant to the healthcare and diagnostics sectors, while the stock market reaction reflects investor attention on executive succession and the company’s financial outlook.
This article reports the company’s statements and market reaction as provided by Danaher; it does not add or infer additional outcomes beyond those disclosed.